Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Operating Leases (2025)

Soleno Therapeutics (SLNO) has disclosed Operating Leases for 1 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Operating Leases changed N/A to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.0 million for FY2025, N/A changed from the prior year.
  • Operating Leases for Q4 2025 was $2.0 million at Soleno Therapeutics, down from $2.1 million in the prior quarter.
  • The five-year high for Operating Leases was $2.4 million in Q1 2025, with the low at $2.0 million in Q4 2025.